At REMD, we believe that
innovative
protein therapeutics and strong science can change the practice of
medicine.
We strive to create new
treatments that are effective,
safe and affordable for patients suffering from
metabolic
diseases and other
serious illnesses.
REMD 477 competitively blocks glucagon
binding to the receptor
binding to the receptor
PNAS (2012) 109: 14393